黄体素市场规模 - 按配方（天然、合成）、给药途径（注射、口服）、应用（避孕、更年期）、药物类型（仿製药、品牌）、类型（处方药、非处方药）、配销通路和预测， 2024 年 - 2032

由于人们对多囊性卵巢症候群 (PCOS)、不孕症和月经不规则等荷尔蒙相关疾病的认识和诊断不断提高，黄体酮市场规模预计在 2024 年至 2032 年间复合年增长率为 12.7%。根据世界卫生组织的数据，到 2023 年，预计多囊性卵巢症候群会影响 8% 至 13% 的育龄女性，其中全球多达 70% 的受影响女性仍未被诊断出来。医疗保健提供者越来越多地开出黄体酮药物来解决这些问题。人口老化和更年期症状的增加进一步需要荷尔蒙替代疗法。

此外，药物配方和药物传输技术的进步正在提高黄体酮产品的功效和安全性，促进其在临床环境中的采用。缓释製剂和透皮贴片等创新提供了便捷的给药途径并提高了患者的依从性。专注于探索黄体酮在癌症治疗、神经病学和精神病学等领域的治疗潜力的不断扩大的研究活动也将推动市场成长。

黄体酮产业根据配方、给药途径、应用、药物类型、类型、配销通路和地区进行分类。

从应用来看，2024年至2032年，避孕领域的市场规模预计将实现13.1%的复合年增长率。推动的。旨在提高黄体酮避孕药的安全性、有效性和便利性的持续研发工作也为产品製造商和利害关係人提供了利润丰厚的机会。

根据类型，OTC 领域的黄体酮产业在 2024 年至 2032 年期间的复合年增长率将达到 12.4%。消费者对女性健康的认识和赋权不断增强，加上获得非处方药产品的便利性，有利于这一增长。此外，无需处方即可获得黄体酮乳膏、凝胶和补充剂，为管理荷尔蒙相关病症提供了更大的自主权，从而扩大了消费者基础。

亚太地区黄体酮产业预计到2032 年将实现12.3% 的成长率，这归因于人口的迅速增长，以及解决多囊性卵巢症候群和不孕症等荷尔蒙相关疾病的意识和获得医疗保健服务的不断提高。家庭规模缩小和生育延迟的文化转变导致越来越多地采用含有黄体酮的荷尔蒙避孕药。此外，印度和中国强大的药品製造业将促进黄体酮药物的本地生产，以确保供应链的弹性和可负担性，并刺激区域产业的成长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 荷尔蒙失调的盛行率不断增加
    • 人们对女性健康的认识不断提高
    • 有利的政府措施和医疗保健政策
  • 产业陷阱与挑战
    • 副作用和安全问题
• 成长潜力分析
• 监管环境
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 公司市占率分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按配方划分，2018 年 - 2032 年

• 主要趋势
• 自然的
• 合成的

第 6 章：市场估计与预测：按管理途径，2018 年 - 2032 年

• 主要趋势
• 可注射
• 口服
• 透皮
• 其他给药途径

第 7 章：市场估计与预测：按应用划分，2018 年 - 2032 年

• 主要趋势
• 停经
• 避孕
• 功能性子宫出血
• 增生性前驱病变
• 子宫内膜癌
• 其他应用

第 8 章：市场估计与预测：按药物类型，2018 - 2032

• 主要趋势
• 品牌化
• 通用的

第 9 章：市场估计与预测：按类型，2018 - 2032

• 处方
• 场外交易

第 10 章：市场估计与预测：按配销通路划分，2018 年 - 2032 年

• 主要趋势
• 医院药房
• 零售药房
• 网路药房

第 11 章：市场估计与预测：按地区划分，2018 年 - 2032 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 中东和非洲其他地区

第 12 章：公司简介

• Alkem Laboratories Ltd.
• Aquatic Group
• Bionpharma Inc.
• Cadila Pharmaceuticals
• Cipla Inc.
• Estrellas Life Sciences Private Limited.
• Eli Lily & Company
• Glenmark Pharmaceuticals Ltd.
• Insud Pharma S.L.U.
• Lupin
• Novo Nordisk A/S
• Teva Pharmaceutical Industries Ltd

Progesterone market size is estimated to witness 12.7% CAGR between 2024 and 2032, owing to increasing awareness and diagnosis of hormone-related disorders, such as polycystic ovary syndrome (PCOS), infertility, and menstrual irregularities. As per WHO, in 2023, PCOS affected an estimated 8 to 13% of reproductive-aged women, with up to 70% of the affected women remaining undiagnosed worldwide. Healthcare providers are increasingly prescribing progesterone medications to address these conditions. The aging population and rising instances of menopausal symptoms are further necessitating hormone replacement therapies.

Moreover, advancements in pharmaceutical formulations and drug delivery technologies are enhancing the efficacy and safety profile of progesterone products, fostering their adoption in clinical settings. Innovations, such as sustained-release formulations and transdermal patches offer convenient administration routes and improved patient compliance. The expanding research activities focused on exploring the therapeutic potential of progesterone in areas like cancer treatment, neurology, and psychiatry will also drive the market growth.

The progesterone industry is classified on the basis of formulation, route of administration, application, drug type, type, distribution channel, and region.

By application, the market size from the contraception segment is poised to witness 13.1% CAGR from 2024 to 2032. This is driven by the increasing global emphasis on family planning initiatives and the growing acceptance of hormonal contraceptives among women. The ongoing R&D efforts aimed at enhancing the safety, efficacy, and convenience of progesterone-based contraceptives are also offering lucrative opportunities for the product manufacturers and stakeholders.

Based on type, the progesterone industry from the OTC segment will record 12.4% CAGR during 2024-2032. The growth is favored by the increasing consumer awareness and empowerment regarding women's health, coupled with the convenience of access to OTC products. Furthermore, the availability of progesterone creams, gels, and supplements without the need for a prescription offers greater autonomy in managing hormone-related conditions, thereby expanding the consumer base.

Asia Pacific progesterone industry is slated to witness a 12.3% growth rate through 2032, attributed to the burgeoning population, coupled with increasing awareness and access to healthcare services to address hormone-related disorders, such as PCOS and infertility. The cultural shifts towards smaller family sizes and delayed childbearing are contributing to the rising adoption of hormonal contraceptives containing progesterone. Additionally, the presence of a robust pharmaceutical manufacturing sector in India and China will foster the local production of progesterone medications for ensuring supply chain resilience and affordability, stimulating the regional industry growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Base estimates & calculations
• 1.3 Data validation
• 1.4 Forecast parameters
• 1.5 Data sources
  • 1.5.1 Primary
  • 1.5.2 Secondary
    • 1.5.2.1 Paid sources
    • 1.5.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Industry 360-degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of hormonal disorders
    • 3.2.1.2 Rising awareness about women's health
    • 3.2.1.3 Favorable government initiatives and healthcare policies
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Side effects and safety concerns
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
  • 3.5.1 Supplier power
  • 3.5.2 Buyer power
  • 3.5.3 Threat of new entrants
  • 3.5.4 Threat of substitutes
  • 3.5.5 Industry rivalry
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Formulation, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Natural
• 5.3 Synthetic

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Injectable
• 6.3 Oral
• 6.4 Transdermal
• 6.5 Other routes of administration

Chapter 7 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Menopause
• 7.3 Contraception
• 7.4 Dysfunctional uterine bleeding
• 7.5 Hyperplastic precursor lesions
• 7.6 Endometrial cancer
• 7.7 Other applications

Chapter 8 Market Estimates and Forecast, By Drug Type, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Branded
• 8.3 Generic

Chapter 9 Market Estimates and Forecast, By Type, 2018 - 2032 ($ Mn)

• 9.1 Prescription
• 9.2 OTC

Chapter 10 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 Hospital pharmacy
• 10.3 Retail pharmacy
• 10.4 Online pharmacy

Chapter 11 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 11.1 Key trends
• 11.2 North America
  • 11.2.1 U.S.
  • 11.2.2 Canada
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 France
  • 11.3.4 Spain
  • 11.3.5 Italy
  • 11.3.6 Rest of Europe
• 11.4 Asia Pacific
  • 11.4.1 China
  • 11.4.2 Japan
  • 11.4.3 India
  • 11.4.4 Australia
  • 11.4.5 Rest of Asia Pacific
• 11.5 Latin America
  • 11.5.1 Brazil
  • 11.5.2 Mexico
  • 11.5.3 Rest of Latin America
• 11.6 Middle East and Africa
  • 11.6.1 South Africa
  • 11.6.2 Saudi Arabia
  • 11.6.3 Rest of Middle East and Africa

Chapter 12 Company Profiles

• 12.1 Alkem Laboratories Ltd.
• 12.2 Aquatic Group
• 12.3 Bionpharma Inc.
• 12.4 Cadila Pharmaceuticals
• 12.5 Cipla Inc.
• 12.6 Estrellas Life Sciences Private Limited.
• 12.7 Eli Lily & Company
• 12.8 Glenmark Pharmaceuticals Ltd.
• 12.9 Insud Pharma S.L.U.
• 12.10 Lupin
• 12.11 Novo Nordisk A/S
• 12.12 Teva Pharmaceutical Industries Ltd